Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
- Sponsor
- Centre Hospitalier Universitaire Vaudois
- Study ID
- NCT02702700
- Phase
- PHASE1
- Status
- Terminated
Conditions
- Pleural Effusion, Malignant
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Cisplatin, liposomal — DRUGLipoplatin IV 200 mg/m2
- Verteporfin — DRUGVisudyne® IV 3 mg/m2
- Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry — DEVICEIntrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of \<10mWcm2.
Study Details
This clinical study aims to explore intrapleural low-dose Visudyne®-mediated photodynamic therapy (photo-induction) as a pathway to promote the uptake of systemically administered Lipoplatin™ in pleural malignancies of patients undergoing video-assisted talcage for their malignant pleural effusions. Photo-induction is expected to overcome the chemo-resistance of pleural malignancies for cisplatin-based chemotherapeutics and thereby improve local tumor control.
Key Dates
- Start date
- Jan 31, 2016
- Status verified
- Mar 2019
- Primary completion
- Aug 28, 2018
- Completion
- Aug 28, 2018
Study Design
- Enrollment
- 1 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Lipoplatin/Visudyne-mediated photodynamic therapy200 mg/m2 Lipoplatin™ will be delivered as iv perfusion. Then, intrapleural photo-induction will be realized through a classical video-assisted thoracoscopic (VATS) approach using 3 mg/m2 Visudyne® activated at 689 nm. At the end of the procedure, the patients will receive chemical pleurodesis by VATS as per standard-of-care treatment for malignant pleural effusion.
Primary Outcome Measure
Safety of the treatment as assessed by 30-day postoperative mortality [ Time Frame: 30 days ]
Related Studies
- Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseasePHASE1 · Recruiting · David Bartlett, MD · Pittsburgh, Pennsylvania
- Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsPHASE1 · Recruiting · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania